February is American Heart Month—a national call to action to address the leading cause of death in the United States. Heart disease kills roughly one person every 34 seconds, claiming over 700,000 lives annually. Yet here’s the hopeful reality: the vast majority of heart disease is preventable through early risk detection and lifestyle or medical management.

The challenge is that cardiovascular disease is often silent. Many people experience their first heart attack or stroke without prior warning symptoms. Blood vessels silently accumulate plaque for years or decades before rupture occurs, making biomarker tracking—measuring cholesterol, inflammation, and metabolic markers through blood tests—essential for early detection.

This article empowers you to understand the biomarkers that reveal cardiovascular risk years before symptoms appear. By owning your cholesterol, inflammation, and metabolic markers, you gain objective data to guide prevention strategies and measure your response to lifestyle changes or medications.

Heart Disease as the Leading Cause of Death

Heart disease encompasses multiple conditions: coronary artery disease (blocked arteries in the heart), heart failure (weakened heart muscle), arrhythmias (irregular heartbeat), and stroke (blocked arteries in the brain). Collectively, these conditions claim roughly 1 in 5 deaths in the United States annually.

What’s sobering is how preventable much of this is. Roughly 90% of first heart attacks are associated with modifiable risk factors: high cholesterol, high blood pressure, diabetes, smoking, obesity, physical inactivity, and poor diet. These aren’t genetic inevitabilities; they’re measurable, addressable health inputs.

Yet many people don’t know their risk status. They assume they’re fine because they feel fine, not realising that plaque accumulation—the precursor to heart attack—causes no symptoms until rupture occurs.

The Role of Early Risk Detection

Early detection of cardiovascular risk allows intervention before disease becomes symptomatic. This is where biomarkers play a transformative role.

Blood tests measure cholesterol levels, inflammation markers, and metabolic factors that quantify heart disease risk. These values don’t predict whether you specifically will have a heart attack, but they indicate your statistical risk in a population of similar people. That information, combined with other factors (age, blood pressure, smoking status), feeds into validated risk calculators that estimate your 10-year cardiovascular risk.

If your risk is elevated, you and your clinician can discuss prevention strategies—lifestyle modifications (diet, exercise, stress management, smoking cessation) or medications (statins, for example, reduce cardiovascular events by 25–35% in high-risk individuals). Monitoring biomarkers over time shows whether these strategies are working and allows adjustments if needed.

This is prevention in its purest form: detecting risk before disease becomes symptomatic, intervening early, and modifying trajectories.

How Heart Disease Develops

Understanding cardiovascular disease’s development mechanism clarifies why biomarkers matter.

LDL Infiltration and Plaque Formation

Atherosclerosis—the underlying cause of most coronary artery disease—is a chronic inflammatory process beginning with LDL (low-density lipoprotein) cholesterol accumulation in artery walls.

Here’s the progression:

LDL infiltrates artery walls: LDL particles carry cholesterol through the bloodstream. In areas of artery wall turbulence or injury, LDL particles infiltrate the inner lining (endothelium) of blood vessels.

LDL becomes oxidised: Once inside the artery wall, LDL undergoes oxidation—a chemical change that makes it recognised as foreign and potentially harmful.

Immune response triggers inflammation: The body’s immune cells (macrophages) detect oxidised LDL and attempt to remove it, engulfing the particles. Over time, accumulation of these cholesterol-laden immune cells creates a fatty streak—the earliest visible sign of atherosclerosis.

Plaque builds: The fatty streak evolves into a fibrous plaque—a complex lesion with a lipid core surrounded by smooth muscle cells and connective tissue. The artery narrows as plaque accumulates, potentially restricting blood flow.

Plaque ruptures: Some plaques develop a thin, rupture-prone fibrous cap. If rupture occurs, the lipid core is exposed, triggering blood clotting on the plaque surface. A clot can suddenly block the artery, cutting off blood supply to heart muscle (myocardial infarction—heart attack) or brain (stroke).

Timeline: This entire process typically unfolds over 10–20 years, making biomarker tracking during this asymptomatic phase crucial for early intervention.

Inflammation and Plaque Instability

Beyond LDL accumulation, inflammation plays a critical role in atherosclerosis. Plaques don’t rupture randomly; plaques with active inflammation are more vulnerable.

hsCRP (high-sensitivity C-reactive protein) is a marker of systemic inflammation. Elevated hsCRP indicates the body is mounting an inflammatory response—whether to infection, autoimmune disease, obesity, or atherosclerotic plaques themselves.

In cardiovascular disease, elevated hsCRP is associated with:

  • More unstable plaques prone to rupture
  • Greater inflammatory activity within atherosclerotic lesions
  • Increased cardiovascular event risk, independent of LDL level

This is why hsCRP adds information beyond cholesterol. Two people with identical LDL levels but different hsCRP values may have different rupture risk profiles. The person with elevated hsCRP has more inflammatory activity feeding plaque instability.

Core Biomarkers That Influence Heart Risk

Several blood tests provide insight into different aspects of cardiovascular risk. Understanding each one builds a complete picture.

LDL-C and Non-HDL Cholesterol

LDL cholesterol (LDL-C) is the primary target of cardiovascular risk reduction. It’s the “bad” cholesterol—the particle most directly linked to atherosclerosis.

Normal/optimal ranges:

  • Optimal: <70 mg/dL (especially for high-risk individuals)
  • Normal: <100 mg/dL
  • Borderline high: 100–129 mg/dL
  • High: 130–159 mg/dL
  • Very high: >160 mg/dL

What LDL-C tells you:

  • Low LDL (<70): Very low risk for atherosclerotic events
  • Borderline LDL (130–159): Marginal risk; lifestyle modification typically recommended as first step
  • High LDL (>160): Significantly increased risk; medication (typically statins) usually recommended

Non-HDL cholesterol is total cholesterol minus HDL (the “good” cholesterol). Non-HDL includes LDL plus other atherogenic particles (VLDL remnants). Non-HDL is increasingly used because it captures more of the “bad” particle burden.

Non-HDL targets: <100 mg/dL for most people; <70 mg/dL for high-risk individuals.

Why non-HDL matters: In people with high triglycerides or other lipid abnormalities, non-HDL may be more informative than LDL alone, capturing atherogenic particle types that LDL testing might miss.

Lipoprotein(a): The Genetic Risk Marker

Lipoprotein(a), pronounced “Lp(a),” is a cholesterol-carrying particle similar to LDL but with additional protein (apolipoprotein(a)) attached. Lp(a) levels are largely genetically determined—inherited from parents—and remain relatively stable throughout life.

Normal/optimal levels:

  • <50 mg/dL: Low genetic risk
  • 50–100 mg/dL: Moderate genetic risk
  • 100 mg/dL: High genetic risk

Why Lp(a) matters:

  • Elevated Lp(a) independently increases cardiovascular risk, even with normal LDL
  • Lp(a) is particularly atherogenic—even more so per-particle than LDL
  • Lp(a) is not well-addressed by current cholesterol medications (statins don’t lower Lp(a) significantly)

Why Lp(a) is often overlooked: Lp(a) is not part of standard lipid panels in many laboratories. If you have elevated cardiovascular risk despite “normal” LDL, or if you have premature coronary disease or family history of early heart attacks, Lp(a) testing is valuable for clarifying genetic risk contribution.

hsCRP and Inflammation

hsCRP (high-sensitivity C-reactive protein) is a measure of systemic inflammation. While not cholesterol-specific, elevated hsCRP correlates with cardiovascular event risk.

Normal/optimal levels:

  • <1 mg/L: Low risk
  • 1–3 mg/L: Average risk
  • 3 mg/L: Elevated inflammation and increased risk

What elevated hsCRP tells you:

  • Your body is mounting an inflammatory response
  • If atherosclerosis is present, plaques may be more active and unstable
  • Cardiovascular event risk is elevated, even accounting for LDL

Why hsCRP is useful beyond LDL: Some people with low LDL but elevated hsCRP have higher event risk than expected from LDL alone. Conversely, some people with higher LDL but very low hsCRP may have lower event risk. hsCRP provides additional risk stratification.

Important limitation: hsCRP is non-specific. Elevated hsCRP can reflect infection, autoimmune disease, obesity, or smoking—not just atherosclerosis. It’s one piece of the risk puzzle, not diagnostic for heart disease.

HbA1c and Metabolic Risk

HbA1c (glycated haemoglobin) measures average blood glucose over roughly 2–3 months. It’s the primary marker for diabetes screening and monitoring.

Categories:

  • <5.7%: Normal glucose metabolism
  • 5.7–6.4%: Prediabetes (increased diabetes risk)
  • ≥6.5%: Diabetes

Why HbA1c is crucial for heart risk: Diabetes dramatically increases cardiovascular risk—roughly 2–4 times higher than non-diabetics with similar cholesterol levels. High blood glucose damages blood vessels, increases inflammation, and accelerates atherosclerosis.

Importantly, prediabetes (HbA1c 5.7–6.4%) is already associated with increased cardiovascular risk, even before meeting diabetes diagnostic criteria. This is why HbA1c matters regardless of diabetes status—it quantifies metabolic health’s contribution to heart risk.

Understanding Your 10-Year ASCVD Risk

The American Heart Association and American College of Cardiology have developed the ASCVD Risk Calculator, a validated tool that synthesises multiple biomarkers and clinical factors into a single estimate: your probability of a cardiovascular event (heart attack or stroke) within the next 10 years.

How Biomarkers Feed the Calculator

The ASCVD calculator inputs include:

  • Age and sex
  • Race/ethnicity (because risk varies by population)
  • Total cholesterol and LDL
  • HDL cholesterol (the protective cholesterol)
  • Blood pressure
  • Diabetes status (HbA1c context)
  • Smoking status

The calculator produces a percentage: your estimated 10-year risk. A 50-year-old man with cholesterol of 200, LDL 130, HDL 40, blood pressure 140/90, diabetes (HbA1c 7.0%), and smoking history might have a 15% 10-year risk—meaning roughly 15 in 100 people with similar profiles will experience a cardiovascular event within a decade.

Why the calculator is useful: It moves risk assessment from abstract (“high cholesterol is bad”) to concrete (“your current profile suggests 15% 10-year risk”). That concreteness makes the case for intervention.

Why 7.5% Risk Matters

Current guidelines suggest considering preventive medication (typically statins) for people with 10-year ASCVD risk ≥7.5%, combined with lifestyle modification. This threshold balances medication benefit (avoiding events in high-risk people) with potential side effects and cost.

What this means:

  • If your risk is <7.5%, lifestyle modification (diet, exercise, smoking cessation, stress management) is typically the primary recommendation
  • If your risk is 7.5–10%, medication discussion is appropriate; shared decision-making between you and your clinician determines whether to start
  • If your risk is >10%, medication is generally recommended in addition to lifestyle modification

Understanding your risk percentage—derived from your biomarkers—makes prevention discussions concrete and data-driven.

Monitoring Response to Lifestyle or Medication

Once you know your baseline biomarker values and cardiovascular risk, the next phase is monitoring whether lifestyle changes or medications are working.

Tracking LDL Reduction (50% Target Context)

For people on statins or other cholesterol-lowering medications, a common target is 50% reduction in LDL from baseline, or achieving LDL <70 mg/dL, whichever is lower.

Example: If your baseline LDL is 160 mg/dL, a 50% reduction targets LDL 80 mg/dL—a substantial decrease that significantly reduces cardiovascular event risk.

Monitoring approach:

  • Baseline lipid panel (before starting medication or major lifestyle change)
  • Repeat testing 4–12 weeks after intervention, allowing time for changes to occur
  • Reassess every 6–12 months once stable

Why tracking matters: You see whether the medication or lifestyle changes are having the intended effect. If LDL is reducing but not meeting targets, dose adjustments or additional medications might be discussed. If LDL remains unchanged despite medication adherence, absorption issues or medication resistance might be investigated.

Watching Inflammation Trends

hsCRP can also be tracked over time, though trends are less directly targeted than LDL.

Inflammation trends often improve with:

  • Weight loss
  • Regular exercise
  • Smoking cessation
  • Mediterranean or DASH dietary patterns
  • Reduced emotional stress

Declining hsCRP over months reflects improving inflammatory status, which may reduce cardiovascular event risk independent of cholesterol changes.

What Lab Tests Can—and Cannot—Predict

Silent Risk vs Symptoms

A critical distinction: cardiovascular biomarkers reveal risk, not necessarily symptoms.

You can have:

  • High LDL with no symptoms (and be at high risk)
  • High hsCRP with no symptoms (indicating inflammatory activity)
  • Elevated HbA1c with no symptoms (whilst glucose damages vessels silently)

Conversely, you can have:

  • Normal cholesterol yet still have significant plaque burden (particularly if Lp(a) is elevated)
  • No family history yet develop early heart disease
  • Perfect biomarkers yet experience a heart attack (though this is rare)

Biomarkers provide statistical risk information. They don’t predict individual outcomes with certainty.

When Imaging Tests May Be Considered

If your biomarker profile suggests elevated risk but you’re uncertain about medication, additional imaging may clarify:

Coronary artery calcium (CAC) score: A CT scan that visualises calcified plaque in coronary arteries. A higher score indicates more plaque burden and potentially higher event risk.

Carotid intima-media thickness (CIMT): Ultrasound measuring artery wall thickness in the neck. Thickening suggests atherosclerosis progression.

Stress testing or coronary angiography: Evaluates whether plaque is causing significant blood flow restriction.

These tests provide direct visualisation of atherosclerosis but aren’t routinely recommended for all people. Biomarkers help clinicians decide who might benefit from imaging.

Taking Ownership of Your Cardiovascular Biomarkers

Cardiovascular disease develops over years and is highly modifiable. Taking ownership of your biomarkers—understanding them, tracking them, and using them to guide prevention—empowers long-term health.

Establishing a Baseline

A comprehensive cardiovascular baseline includes:

  • Lipid panel: Total cholesterol, LDL, HDL, triglycerides
  • Lp(a): Often not routine; ask specifically if risk factors are present
  • hsCRP: Adds inflammation context
  • Glucose or HbA1c: Metabolic health assessment
  • Blood pressure: Critical risk factor
  • BMI and waist circumference: Obesity assessment

Baseline values become your reference point. Future tests are compared to this starting point, showing whether values are improving, stable, or worsening.

Ask your healthcare provider for copies of all results. Record the values (date, LDL, HDL, triglycerides, hsCRP, HbA1c, blood pressure). This becomes your cardiovascular health history—visual evidence of your risk profile and its changes.

Tracking Trends Over Time

The real power of biomarker monitoring emerges from longitudinal tracking—seeing trends over months or years.

Positive trends:

  • LDL declining with medication adherence or dietary improvement
  • hsCRP dropping with weight loss and exercise
  • HbA1c improving with diabetes management
  • Blood pressure normalising with salt reduction and stress management

Concerning trends:

  • LDL creeping upward despite medication
  • hsCRP persistently elevated despite lifestyle efforts
  • HbA1c rising, suggesting worsening glucose control
  • Blood pressure uncontrolled despite medication

Trends inform discussions with your clinician. Rising LDL despite statin use might prompt dose increase or additional medication. Elevated HbA1c despite diet efforts might warrant diabetes medication initiation. Persistent high blood pressure despite lifestyle modifications might require additional antihypertensive drugs.

A Note on Testing and Cardiovascular Health

The information in this article is educational and meant to support informed conversations with your healthcare provider, not replace clinical evaluation or guide independent medical decisions. Cardiovascular risk assessment, interpretation of biomarkers, and treatment recommendations require professional clinical judgment that accounts for your full health history, symptoms, and individual circumstances.

If you’re uncertain about your cardiovascular risk status, speak with your primary care doctor or cardiologist. They can assess your individual situation, order appropriate testing, interpret results within clinical context, and recommend personalised prevention strategies.

Organisations like the American Heart Association, the American College of Cardiology, and the CDC provide evidence-based cardiovascular disease prevention information. Consulting these resources alongside professional medical guidance ensures you have accurate, current information.

Key Takeaways

  • Heart disease is common but largely preventable through early risk detection and lifestyle or medical intervention. Many first heart attacks occur without prior warning symptoms, making biomarker tracking essential.
  • LDL cholesterol is the primary atherosclerosis driver. Optimal LDL is <70 mg/dL for most people, though individual targets vary based on overall risk.
  • Lipoprotein(a) is a genetically determined cardiovascular risk factor that’s not addressed by standard cholesterol medications and warrants testing in high-risk individuals.
  • hsCRP measures systemic inflammation associated with plaque instability and cardiovascular event risk, providing risk stratification beyond cholesterol alone.
  • HbA1c reflects metabolic health and dramatically increases cardiovascular risk when elevated. Even prediabetes (HbA1c 5.7–6.4%) carries increased heart disease risk.
  • ASCVD risk calculators synthesise biomarkers and clinical factors into a 10-year risk estimate, making risk assessment concrete and actionable.
  • Statin therapy reduces cardiovascular events by 25–35% in high-risk individuals, with response monitored by LDL levels (target: 50% reduction or <70 mg/dL).
  • Cardiovascular disease develops silently over years. Baseline biomarker assessment and periodic monitoring support early intervention before disease becomes symptomatic.

This American Heart Month, if you haven’t had a lipid panel or HbA1c in recent years, schedule one. Know your numbers. If your ASCVD risk is elevated, discuss prevention strategies—lifestyle modifications or medication—with your clinician. If you’re on medications, understand your targets and track your progress.

Your cardiovascular biomarkers are measurable, modifiable inputs into your long-term health trajectory. By owning them, monitoring them, and using them to guide prevention, you’re taking the most powerful step possible toward protecting your heart.